---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-087221"
form_type: "8-K"
ticker: "COCH"
cik: "0001840877"
company_name: "Envoy Medical, Inc."
filed_at: "2026-08-10T20:01:14+00:00"
generated_at: "2026-08-10T20:03:43.901856+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Envoy Medical posts Q2 loss, submits first FDA PMA module for Acclaim implant

## Summary
- Q2 2026 net loss of $7.27M ($0.07/share) vs $6.94M ($0.32/share) in Q2 2025; revenue only $51K.
- Submitted first of four modular PMA modules to FDA for Acclaim cochlear implant; final module targeted Q2 2027.
- 12-month Stage 1 data: mean CNC word score 53.2% vs 15.2% baseline (38.0 pp gain), up from 24.0 pp at 6 months.
- R&D spending rose to $3.13M from $2.49M on clinical trial and PMA work; cash ~$19.7M at June 30.
- Terminated $15M ATM equity facility; 4 patents granted in Australia and Europe.

## SEC filing metadata
- accession: 0001213900-26-087221
- form_type: 8-K
- ticker: COCH
- cik: 0001840877
- company_name: Envoy Medical, Inc.
- filed_at: 2026-08-10T20:01:14+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840877/000121390026087221/0001213900-26-087221-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840877/000121390026087221/ea0301372-8k_envoy.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-087221
- JSON: https://secwatch.observer/filing/0001213900-26-087221.json
- Plain text: https://secwatch.observer/filing/0001213900-26-087221.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.